Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

nt with Janssen, total amounts in excess of the annual cap ("Excess Amounts") plus interest may not exceed $225 million.

The Company has recognized the Excess Amounts as a reduction to operating expenses in the current year as the Company's repayment of the Excess Amounts to Janssen is contingent and would become payable only after the third profitable calendar quarter for the product under the collaboration. Further, the Excess Amounts shall be reimbursable only from the Company's share of future full calendar quarter pre-tax profits (if any) after the third profitable calendar quarter for the product under the collaboration.

For the calendar year ended December 31, 2012, the Company's total share of collaboration expenses under the Agreement was $68.1 million. As of December 31, 2012, total Excess Amounts totaled $18.1 million, of which during the quarter ended December 31, 2012, $17.3 million was recorded as a reduction to research and development expense and $0.8 million was recorded as a reduction to general and administrative expense.

GAAP operating expenses were $40.6 million for the six months ended December 31, 2012, compared to $30.6 million for the six months ended December 31, 2011. Included in operating expenses for the six months ended December 31, 2012 is the $18.1 million reduction to operating expenses for Excess Amounts.

GAAP operating expenses were $16.7 million for the quarter ended December 31, 2012, compared to $16.0 million for the quarter ended December 31, 2011 and $23.9 million for the quarter ended September 30, 2012. Included in operating expenses for the quarter ended December 31, 2012 is the $18.1 million reduction to operating expenses for the Excess Amounts.

At December 31, 2012, the Company had cash, cash equivalents and marketable securities of $317.1 million, compared with $203.6 million at June 30, 2012. In addition, as of December 31, 2012, the Company had $26.6 million receivable from Jansse
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... is rarely simple. From crop yields to disease risks, ... those considered "complex traits." Just as for heightthe textbook ... particular human disease are shaped by multiple genetic and ... involved. To track down such genes, geneticists typically mate ... large mouse and a small mouseand then study their ...
(Date:9/19/2014)... NEW YORK , Sept. 19, 2014  An ... common forms of inherited neuropathies – Charcot-Marie-Tooth disease (CMT) ... feet and legs, causing extreme muscle atrophy, weakness, and ... in the US and millions worldwide. CMT is a ... use of their legs, requiring mobility devices such as ...
(Date:9/19/2014)... BioTech News Coverage: Progress made ... of studies and trials.  Companies in focus are: GenSpera ... LLY ), Gilead Sciences Inc. (NASDAQ: ... and Arena Pharmaceuticals Inc. (NASDAQ: ARNA) GenSpera, ... for the treatment of cancer, announced that the United ...
(Date:9/19/2014)... Massachusetts , September 19, 2014 ... the 53rd European Society for Paediatric Endocrinology (ESPE) Meeting  ... of science and medical research in the field of ... Merck KGaA, Darmstadt, Germany , today ... Innovation (GGI) for 2014. The awards were announced during ...
Breaking Biology Technology:Want to link genes to complex traits? Start with more diversity 2September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3
... an advanced,biomaterials company, announced today that it has ... Under the agreement, LifeNet Health will provide ... mixed with ETEX,s proprietary,calcium phosphate to form a ... EquivaBone(TM) in its Cambridge,facilities and market the product ...
... Corporation,(Nasdaq: IOMI ) today announced that it will ... markets open and hold a,conference call and live webcast ... 2008 at 1:30 p.m. Eastern Time., Conference Call ... Thursday, March 6 at 1:30 p.m.,Eastern Time via phone, ...
... /PRNewswire/ - BIKAM,pioneers in the discovery and ... of degenerative eye diseases and ocular disorders ... exclusive worldwide,collaboration and agreement to discover and ... Dalton Medicinal Chemistry will utilize their ...
Cached Biology Technology:ETEX and LifeNet Health, Inc. Enter Agreement 2Iomai to Announce Fourth Quarter and Year-End 2007 Financial Results and Host Webcast on Thursday, March 6 2BIKAM and Dalton Medicinal Chemistry Sign Collaborative Research Agreement 2
(Date:9/18/2014)... Worcester, Mass. A novel robotic system that can ... currently being tested as part of a biomedical research ... with the aim of determining if the robot, in ... biopsies faster, more accurate, less costly, and less discomforting ... potential to deliver prostate cancer therapies with greater precision. ...
(Date:9/18/2014)... No matter how many times it,s demonstrated, ... communicating creatures. , But by using a ... radically alter their behavior to suit their population. ... them are present, and act accordingly. , Once ... it may change from innocuous to pathogenic, or ...
(Date:9/18/2014)... is stored in DNA, tiny strands of nucleic acid ... To express this genetic data, our DNA is copied ... proteins that perform tasks in our cells. , ... RNA molecule. Unlike all other known RNAs, this molecule ... molecules are abundant, little has been known about how ...
Breaking Biology News(10 mins):Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2
... a pretzel factory production line, with conveyer belts carrying the dough, ... Now imagine what would happen if pretzel dough started ... conveyor, misshapen, and sticking fast to the dough of the other ... mess could no longer be conveyed into the oven, the backup ...
... CRUZ, CA--An intricate three-way mating struggle first observed in ... in a distant relative, the European common lizard. The ... million years of evolution, yet they share behavioral and ... the males, according to new research published in the ...
... the University of Warwick have devised a means of ... in just a few seconds. Previous techniques have ... finger print and laboriously match them against a database ... entire detailed pattern of each print and transform the ...
Cached Biology News:Botched production of insulin molecule may lead to diabetes 2Botched production of insulin molecule may lead to diabetes 3Botched production of insulin molecule may lead to diabetes 4Three-way mating game of North American lizard found in distant European relative 2Three-way mating game of North American lizard found in distant European relative 3Three-way mating game of North American lizard found in distant European relative 4New technology identifies warped fingerprints at warp speed 2
Blot Paper 7 x 8.5cm semi-dry western blots (order number RB-400)...
... provide rapid and efficient removal of short ... salts from PCR products (Figure 1). The ... Binding Buffer options for fragments >100 bp ... in either single column or 96-well plate ...
... with the translation boosting Cap 1 structure. ... (versus 40% to 80% capped using co-transcriptional ... hours. mScript™ also features the Cap 1 ... up to 50% more efficient in in ...
... Expression System with Gateway™ Technology is ... containing the polyhedrin promoter. The expression ... genome (bacmid DNA) by site-specific transposition ... The recombinant bacmid DNA is then ...
Biology Products: